Bruker Corporation - BRKR STOCK NEWS

Bruker (Nasdaq: BRKR) announces significant advancements in 4D-Proteomics at the 23rd Human Proteome Organization World Congress. Key developments include:

1. Enhanced specificity and proteome coverage using diagonal-PASEF.
2. Achievement of a one-hundred dollar deep, high-accuracy plasma proteome analysis.
3. Introduction of high-sensitivity plasma glycopeptide analysis on timsTOF Ultra 2.
4. Increased peptide and protein identifications with ML-enhanced TIMSrescore.
5. Introduction of multiomics visualization and insights for proteomics and metabolomics.

These advancements enable robust, unbiased, and affordable proteomics with high-specificity protein identification and quantification, suitable for large-scale plasma proteomics studies.

Bruker (Nasdaq: BRKR) announced that the European Unified Patent Court (UPC) has ruled in favor of its NanoString business, invalidating European Patent No. 2794928B1 (the '928 Patent') asserted by 10x Genomics against NanoString's CosMx® Spatial Molecular Imager (SMI) products in Europe. This ruling follows a similar decision by the German Federal Patent Court in May 2024, which declared the patent invalid in Germany. The UPC's decision extends the invalidation to France and The Netherlands.

The ruling is subject to appeal. Bruker awaits an additional hearing on a related patent (European Patent 4108782B1) and expects it to be declared invalid as well. The European Patent Office has issued a preliminary opinion considering this patent invalid, with a hearing scheduled for March 18, 2025.

Bruker (Nasdaq: BRKR) has announced the formation of a new division, Bruker Spatial Biology, offering comprehensive solutions for spatial biology research. This division brings together NanoString Technologies, Canopy Biosciences, and Bruker Spatial Genomics (formerly Acuity Spatial Genomics).

The new division will focus on advancing biomedical research with a suite of spatial biology instruments, assays, software, data analytics, and CRO services. Its portfolio includes NanoString's GeoMx®, CosMx™, and AtoMx™, Canopy Biosciences' CellScape™, and NanoString's nCounter® for gene expression analysis.

Bruker Spatial Biology aims to provide tailored solutions for customers' unique spatial research needs, offering choices across the spectrum from discovery to translational research. The division will showcase its technologies at the Society for Immunotherapy of Cancer (SITC) 2024 from November 8-10 in Houston, Texas.

Bruker (Nasdaq: BRKR) has unveiled the OptoVolt™ module at the Neuroscience 2024 conference, enhancing their Ultima multiphoton microscope platform for advanced neuroscience research. This innovative solution enables imaging speeds beyond 1000 frames per second, allowing researchers to capture millisecond dynamics of neural communication at single neuron resolution.

The OptoVolt module addresses challenges in voltage imaging with its ultrafast scanner technology and high signal-to-noise ratio. When combined with Bruker's NeuraLight 3D Ultra® spatial light modulator, it enables researchers to probe input-output relationships of neural ensembles at unprecedented temporal and spatial resolutions.

Professor Thomas Clandinin from Stanford University expressed excitement about the potential of voltage imaging in neural circuit investigation and systems neuroscience. Xiaomei Li, Ph.D., Vice President at Bruker, emphasized the company's commitment to addressing evolving research needs through customer collaboration.

Bruker (Nasdaq: BRKR) has acquired Dynamic Biosensors GmbH, a Munich-based pioneer in biosensor development. This acquisition enhances Bruker's biophysical portfolio for analyzing molecular interactions and kinetics in drug discovery and basic research. Dynamic Biosensors' innovative technologies include:

1. The heliXcyto instrument for single-cell Interaction Cytometry (scIC)
2. The heliX+ instrument using switchSENSE® technology with DNA nanolevers

These complement Bruker's Surface Plasmon Resonance (SPR) portfolio, including the new SPR #64 'Triceratops' and Sierra-Pro SPR systems. The combined Bruker Biosensors business now offers a comprehensive range of instruments, workflows, and consumables for studying inter-molecular and molecule-cell interactions in drug discovery. Financial details were not disclosed, but Bruker expects additional revenues greater than $5 million from the acquisition in FY2025, with no material EPS impact.

Bruker (Nasdaq: BRKR) has announced its participation in two upcoming investor conferences. Gerald Herman, Executive Vice President & CFO, will represent the company at both events:

1. The 2024 Wells Fargo Healthcare Conference in Boston, MA on Wednesday, September 4, 2024, at 10:15 a.m. Eastern Time.

2. The Morgan Stanley 22nd Annual Global Healthcare Conference in New York City on Friday, September 6, 2024, at 10:00 a.m. Eastern Time.

Live audiovisual webcasts of the presentations will be available on the company's Investor Relations website. Replays will be accessible for 90 days after the events in the 'Events & Presentations' section.

Bruker has successfully installed Asia's first 1.2 GHz Avance® Nuclear Magnetic Resonance (NMR) spectrometer at the Korea Basic Science Institute (KBSI). This ultra-high field NMR system sets a new benchmark for molecular, cell biology, and disease research in the Asia-Pacific region. The installation enhances KBSI's capabilities in biomolecular structure analysis and drug development, enabling researchers to observe functional molecular dynamics and structural rearrangements in real time.

The 1.2 GHz NMR spectrometer will support various research applications, including the study of intrinsically disordered proteins, drug-target binding mechanisms, and the development of diagnostic methods for infectious diseases. With this installation, there are now 22 GHz-class NMR spectrometers worldwide, highlighting the growing importance of advanced NMR technology in scientific research.

Bruker (Nasdaq: BRKR) has announced a quarterly cash dividend of $0.05 per share on its common stock. The dividend is set to be paid on September 16, 2024, to stockholders of record as of September 2, 2024. This decision, approved by Bruker's Board of Directors, demonstrates the company's commitment to returning value to its shareholders through regular dividend payments.

Bruker (Nasdaq: BRKR) has announced a strategic minority investment in NovAliX, a preclinical Contract Research Organization (CRO) specializing in drug discovery services. The investment aims to accelerate NovAliX's growth and expansion in Europe and the United States. The partnership will focus on developing novel drug discovery technologies and methods, leveraging biophysical methods, particularly NMR.

Key collaboration areas include:

• Ultra-high field NMR for structural and binding investigations
• NMR-powered medicinal chemistry and mechanism of action research
• X-ray crystallography for structure-guided drug discovery
• High-sensitivity SPR for kinetics and binding studies
• Mass spectrometry for proteomics and multiomics
• Single cell and spatial biology tools for drug discovery insights

The partnership aims to enable new paradigms in drug discovery, accelerate development of advanced biophysical methods, and support the discovery of new and better medicines.